Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177908 | 1.00 | EPHX2 (0.44) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL178031 | 0.90 | ALDH1A1 (0.46) | NPC1RAB9ATP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL178134 | 0.90 | ALDH1A1 (0.46) | NPC1RAB9ATP53SMN1; SMN2L3MBTL1 | |
| SCHEMBL13127212 | 0.89 | EPHX2 (0.42) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL10108725 | 0.89 | P2RX7 (0.45) | EPHX2P2RX7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1595367 | 0.89 | EPHX2 (0.41) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL1594704 | 0.89 | EPHX2 (0.41) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL1595001 | 0.88 | EPHX2 (0.43) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL1595898 | 0.88 | EPHX2 (0.43) | EPHX2P2RX7NPC1RAB9ATP53 | |
| SCHEMBL178040 | 0.88 | RAB9A (0.46) | EPHX2P2RX7NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | claimed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | claimed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | claimed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | claimed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | claimed |
| EP-2569281-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | Affectis Pharmaceuticals AG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-102395562-A | Novel P2X7R antagonists and uses thereof | AFFECTIS PHARMACEUTICALS AG | 2012-03-28 | — | — | CN | disclosed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | P2RX7, P2RX3, P2RX2 | EPHX2 869/4885P2RX7 1/4885NPC1 2234/4885 |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | EPHX2 1405/4885P2RX7 4/4885NPC1 1162/4885 |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | EPHX2 1405/4885P2RX7 4/4885NPC1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.